Research ExplorerPublicationsA new molecular predictor of distant recurrence in ER-positi...

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Standard

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. / Filipits, Martin; Rudas, Margaretha; Jakesz, Raimund; Dubsky, Peter; Fitzal, Florian; Singer, Christian F; Dietze, Otto; Greil, Richard; Jelen, Andrea; Sevelda, Paul; Freibauer, Christa; Müller, Volkmar; Jänicke, Fritz; Schmidt, Marcus; Kölbl, Heinz; Rody, Achim; Kaufmann, Manfred; Schroth, Werner; Brauch, Hiltrud; Schwab, Matthias; Fritz, Peter; Weber, Karsten E; Feder, Inke S; Hennig, Guido; Kronenwett, Ralf; Gehrmann, Mathias; Gnant, Michael; Investigators, EP.

In: CLIN CANCER RES, Vol. 17, No. 18, 18, 2011, p. 6012-6020.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Filipits, M, Rudas, M, Jakesz, R, Dubsky, P, Fitzal, F, Singer, CF, Dietze, O, Greil, R, Jelen, A, Sevelda, P, Freibauer, C, Müller, V, Jänicke, F, Schmidt, M, Kölbl, H, Rody, A, Kaufmann, M, Schroth, W, Brauch, H, Schwab, M, Fritz, P, Weber, KE, Feder, IS, Hennig, G, Kronenwett, R, Gehrmann, M, Gnant, M & Investigators, EP 2011, 'A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.', CLIN CANCER RES, vol. 17, no. 18, 18, pp. 6012-6020. <http://www.ncbi.nlm.nih.gov/pubmed/21807638?dopt=Citation>

APA

Filipits, M., Rudas, M., Jakesz, R., Dubsky, P., Fitzal, F., Singer, C. F., Dietze, O., Greil, R., Jelen, A., Sevelda, P., Freibauer, C., Müller, V., Jänicke, F., Schmidt, M., Kölbl, H., Rody, A., Kaufmann, M., Schroth, W., Brauch, H., ... Investigators, EP. (2011). A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. CLIN CANCER RES, 17(18), 6012-6020. [18]. http://www.ncbi.nlm.nih.gov/pubmed/21807638?dopt=Citation

Vancouver

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. CLIN CANCER RES. 2011;17(18):6012-6020. 18.

Bibtex

@article{ef070bde771144c48d23f762e4efa933,
title = "A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.",
abstract = "According to current guidelines, molecular tests predicting the outcome of breast cancer patients can be used to assist in making treatment decisions after consideration of conventional markers. We developed and validated a gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer treated with adjuvant endocrine therapy.",
keywords = "Humans, Female, Risk Factors, Reproducibility of Results, Prognosis, Proportional Hazards Models, Neoplasm Metastasis, Kaplan-Meier Estimate, Gene Expression Profiling/methods, Breast Neoplasms/genetics/mortality/*pathology, Receptor, erbB-2/*genetics, Receptors, Estrogen/*genetics, Humans, Female, Risk Factors, Reproducibility of Results, Prognosis, Proportional Hazards Models, Neoplasm Metastasis, Kaplan-Meier Estimate, Gene Expression Profiling/methods, Breast Neoplasms/genetics/mortality/*pathology, Receptor, erbB-2/*genetics, Receptors, Estrogen/*genetics",
author = "Martin Filipits and Margaretha Rudas and Raimund Jakesz and Peter Dubsky and Florian Fitzal and Singer, {Christian F} and Otto Dietze and Richard Greil and Andrea Jelen and Paul Sevelda and Christa Freibauer and Volkmar M{\"u}ller and Fritz J{\"a}nicke and Marcus Schmidt and Heinz K{\"o}lbl and Achim Rody and Manfred Kaufmann and Werner Schroth and Hiltrud Brauch and Matthias Schwab and Peter Fritz and Weber, {Karsten E} and Feder, {Inke S} and Guido Hennig and Ralf Kronenwett and Mathias Gehrmann and Michael Gnant and EP Investigators",
year = "2011",
language = "English",
volume = "17",
pages = "6012--6020",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

RIS

TY - JOUR

T1 - A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

AU - Filipits, Martin

AU - Rudas, Margaretha

AU - Jakesz, Raimund

AU - Dubsky, Peter

AU - Fitzal, Florian

AU - Singer, Christian F

AU - Dietze, Otto

AU - Greil, Richard

AU - Jelen, Andrea

AU - Sevelda, Paul

AU - Freibauer, Christa

AU - Müller, Volkmar

AU - Jänicke, Fritz

AU - Schmidt, Marcus

AU - Kölbl, Heinz

AU - Rody, Achim

AU - Kaufmann, Manfred

AU - Schroth, Werner

AU - Brauch, Hiltrud

AU - Schwab, Matthias

AU - Fritz, Peter

AU - Weber, Karsten E

AU - Feder, Inke S

AU - Hennig, Guido

AU - Kronenwett, Ralf

AU - Gehrmann, Mathias

AU - Gnant, Michael

AU - Investigators, EP

PY - 2011

Y1 - 2011

N2 - According to current guidelines, molecular tests predicting the outcome of breast cancer patients can be used to assist in making treatment decisions after consideration of conventional markers. We developed and validated a gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer treated with adjuvant endocrine therapy.

AB - According to current guidelines, molecular tests predicting the outcome of breast cancer patients can be used to assist in making treatment decisions after consideration of conventional markers. We developed and validated a gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer treated with adjuvant endocrine therapy.

KW - Humans

KW - Female

KW - Risk Factors

KW - Reproducibility of Results

KW - Prognosis

KW - Proportional Hazards Models

KW - Neoplasm Metastasis

KW - Kaplan-Meier Estimate

KW - Gene Expression Profiling/methods

KW - Breast Neoplasms/genetics/mortality/pathology

KW - Receptor, erbB-2/genetics

KW - Receptors, Estrogen/genetics

KW - Humans

KW - Female

KW - Risk Factors

KW - Reproducibility of Results

KW - Prognosis

KW - Proportional Hazards Models

KW - Neoplasm Metastasis

KW - Kaplan-Meier Estimate

KW - Gene Expression Profiling/methods

KW - Breast Neoplasms/genetics/mortality/pathology

KW - Receptor, erbB-2/genetics

KW - Receptors, Estrogen/genetics

M3 - SCORING: Journal article

VL - 17

SP - 6012

EP - 6020

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 18

M1 - 18

ER -